Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3869206 | 0.81 | LMNA (0.33) | MAPTNPC1RAB9ALMNATSHR | |
| SCHEMBL16875778 | 0.80 | KCNA3 (0.33) | KDM4EMAPT | |
| SCHEMBL8366034 | 0.76 | ALDH1A1 (0.42) | PTPRCKDM4EMAPTNPC1RAB9A | |
| SCHEMBL20288064 | 0.73 | KDM4E (0.38) | KDM4EMAPTMAPK1 | |
| SCHEMBL1900258 | 0.73 | CYP2C19 (0.42) | PTPRCKDM4EMAPTLMNATSHR | |
| SCHEMBL17358865 | 0.73 | CYP2C19 (0.42) | PTPRCKDM4EMAPTLMNATSHR | |
| SCHEMBL20428806 | 0.72 | MAPT (0.40) | KDM4EMAPTMAPK1 | |
| SCHEMBL3170817 | 0.72 | APP (0.38) | KDM4EMAPTLMNATSHR | |
| SCHEMBL14374554 | 0.71 | APP (0.40) | KDM4EMAPTLMNATSHR | |
| SCHEMBL3164545 | 0.71 | ALDH1A1 (0.43) | MAPTLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482490-B2 | Amine compound having fluorene group as framework, process for producing the amine compound, and use of the amine compound | TOSOH CORPORATION (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20080194878-A1 | Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound | TOSOH CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1752440-A1 | AMINE COMPOUND HAVING FLUORENE GROUP AS FRAMEWORK, PROCESS FOR PRODUCING THE AMINE COMPOUND, AND USE OF THE AMINE COMPOUND | Tosoh Corporation (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194878-A1 | Amine Compound Having Fluorene Group as Framework, Process for Producing the Amine Compound, and Use of the Amine Compound | TAAR1, SLC18A1, ADRB2 | PTPRC 4620/4885KDM4E 3513/4885MAPT 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.